MHIG targets healthcare cost inflation specifically, aiming to protect purchasing power against medical expense increases that consistently outpace general CPI. This addresses a critical gap since healthcare inflation has averaged 2-3x broader inflation over the past decade.
How It Works
The fund likely combines healthcare sector equities, medical REITS, pharma/biotech positions, and potentially healthcare-linked bonds or derivatives to track medical cost increases. Given Milliman's actuarial expertise, expect sophisticated weighting based on actual healthcare spending patterns rather than simple market cap. The strategy probably adjusts holdings based on Medicare/Medicaid pricing updates and private insurance trend data.
Key Features
- Pure-play healthcare inflation hedge versus mixing it into broader TIPS exposure
- Zero expense ratio suggests this is a strategic launch product or has embedded costs elsewhere
- Milliman's actuarial background brings unique healthcare cost modeling expertise
Risks
- Healthcare policy changes could crater returns - single payer or drug pricing caps would fundamentally break the thesis
- Concentration risk if heavily weighted toward specific subsectors like hospitals or insurers facing disruption
- Brand new fund with no track record launching into uncertain regulatory environment
Who Should Own This
Retirees facing escalating medical costs need this more than working-age investors with employer coverage. Also fits endowments funding healthcare obligations or anyone with known future medical expenses. Less useful for those betting on healthcare innovation actually reducing costs long-term.